BioSpace News Archive

Agilent Technologies Inc. (NYSE: A) today introduced a multimode real-time cell analyzer (RTCA)—the first of its kind—combining the best of non-invasive biosensor measurement with live cell imaging.

Trovagene, Inc. (Nasdaq: TROV), today announced that new clinical data from its Phase 2 trial of onvansertib, in combination with Zytiga® (abiraterone acetate)/prednisone, in metastatic Castration-Resistant Prostate Cancer (mCRPC), will be presented as an oral poster at the 20th Asia-Pacific Prostate Cancer Conference, which will be held August 23-26 in Melbourne, Australia.

Aperiomics, today announced the appointment of Dr. C. Alexander Valencia, PhD to the position of Chief Clinical Officer, where he will oversee clinical test development, validations, regulatory affairs and operations on behalf of the company.

A+ Family Dentistry announced today that in addition to their locations in Poway and San Diego, they’re opening a third office in Sorrento Valley in mid-August.

CashMD today announced the launch of cashmd.com, a one-of-a-kind online healthcare platform offering transparent pricing for virtually all healthcare-related procedures in a desired location

Regen BioPharma Inc. (OTCQB: RGBP) and (OTCQB: RGBPP), announced today data demonstrating its unique combination of NR2F6 inhibition together with cannabidiol decreases cancer metastasis in an animal model of cancer surgery.

CNSI, a leading business solutions provider with vast experience developing and delivering innovative health information technology solutions, announced today that Melissa Fannin has joined the company as Senior Vice President of Federal Business Development.

PointClickCare, the leading cloud-based software vendor for the long-term and post-acute care (LTPAC) and senior living markets, announced today the results of its 2019 Patient Transition Study, conducted in partnership with Definitive Healthcare

Providence Health & Services, to advance specialty pharmacy services at the Providence Health affiliates in Washington, Montana and Oregon.

preCARDIA, Inc., a medical device company developing innovative technologies for the treatment of acute decompensated heart failure (ADHF), has enrolled the first patient in the VENUS-HF Early Feasibility Study at Tufts Medical Center in Boston by Dr. Carey Kimmelstiel, Director, Interventional Cardiology Center, and Dr. Michael Kiernan, Director, Ventricular Assist Device Program.